CASC3 and mantle cell lymphoma: Although several factors support the strategy of combining CAL-101 with proteasome inhibitors in non-Hodgkin’s lymphoma (NHL), including MCL, the effect of CAL-101 when combined with BTZ on MCL cells remains unknown.